Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Verzoni, Elena
Iacovelli, Roberto
Rizzo, Mimma
Felici, Alessandra
Cascinu, Stefano
Di Lorenzo, Giuseppe
Cerbone, Linda
Ortega, Cinzia
Masini, Cristina
Giganti, Maria Olga
Lorusso, Vito
Messina, Caterina
Atzori, Francesco
De Vincenzo, Fabio
Sacco, Cosimo
Boccardo, Francesco
Valduga, Francesco
Massari, Francesco
Tassi, Renato
Procopio, Giuseppe
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Univ Roma La Sapienza, Dept Radiol Oncol & Human Pathol, Oncol Unit, I-00185 Rome, Italy
[3] Cardarelli, Oncol, Naples, Italy
[4] Regina Elena Inst Canc Res, Rome, Italy
[5] Osped Riuniti Umberto I GM Lancisi & G Salesi, Azienda Osped Univ, Polytech Univ Marche Reg, Dept Med Oncol, Ancona, Italy
[6] Univ Naples Federico II, Dept Oncol, Naples, Italy
[7] San Camillo & Forlanini Hosp, Rome, Italy
[8] Inst Canc Res & Treatment, Turin, Italy
[9] Univ Modena & R Emilia, AO Univ Policl Modena, Modena, Italy
[10] Osped Niguarda Ca Granda, Milan, Italy
[11] Vito Fazzi Hosp, Inst Oncol, Lecce, Italy
[12] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[13] Univ Hosp Cagliari, Cagliari, Italy
[14] Ist Clin Humanitas, Dept Oncol, Milan, Italy
[15] Univ Hosp Udine, Udine, Italy
[16] Univ Genoa, Natl Inst Canc Res, Genoa, Italy
[17] Osped Civ Santa Chiara, Trento, Italy
[18] Univ Florence, Florence, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.431
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
431
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC)
    Sidhu, R.
    Rong, A.
    Dahlberg, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] OVERALL SURVIVAL (OS) VERSUS PROGRESSION-FREE SURVIVAL (PFS): IS THERE A RATIONAL FOR REPLACING ONE OUTCOME FOR THE OTHER?
    Teich, V
    Fernandes, R. A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A863 - A863
  • [33] Examples of Population Kinetics (PopKin) Assessments of Progression-Free (PFS) and Overall Survival (OS)
    Stewart, D.
    Aljassim Alshareef, A.
    Robinson, A.
    Fung-Kee-Fung, M.
    Ong, M.
    Awan, A.
    Ocana, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1213 - S1213
  • [34] PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bex, Axel
    Blank, Christian
    Chowdhury, Simon
    Nichol, David
    Peters, John
    Horenblas, Simon
    O'Brien, Tim
    Sarwar, Naveed
    Haanen, John
    Powles, Thomas
    [J]. JOURNAL OF UROLOGY, 2011, 185 (04): : E709 - E710
  • [35] Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective US chart review.
    Yang, Hongbo
    Wong, Michael K. K.
    Signorovitch, James E.
    Wang, Xufang
    Liu, Zhimei
    Liu, Nathan S.
    Qi, Zhengyun
    George, Daniel J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Association between treatment effects on disease progression (DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Delea, T. E.
    Khuu, A.
    Kay, A.
    Zheng, J.
    Baladi, J. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Association between biopsychosocial distress (BPSD) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Bergerot, C. D.
    Clark, K. L.
    Ashing, K. T.
    Almeida, L.
    Bergerot, P. G.
    Obenchain, R.
    Dizman, N.
    Hsu, J.
    Maia, M. C.
    Philip, E.
    Loscalzo, M.
    Pal, S. K.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [38] Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma
    McAlister, Renee K.
    Aston, Jonathan
    Pollack, Megan
    Du, Liping
    Koyama, Tatsuki
    Chism, David D.
    [J]. ONCOLOGIST, 2018, 23 (06): : 686 - 692
  • [39] Prognostic factors for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC): Results from the French randomized phase II study TORAVA.
    Escudier, B. J.
    Negrier, S.
    Perol, D.
    Gravis, G.
    Delva, R.
    Bay, J.
    Geoffrois, L.
    Legouffe, E.
    Metzger, S.
    Ferlay, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC)
    Kucharz, Jakub
    Dumnicka, Paulina
    Kusnierz-Cabala, Beata
    Demkow, Tomasz
    Wiechno, Pawel
    [J]. MEDICAL ONCOLOGY, 2019, 36 (02)
12345